A recent analysis showed that aftercare strategies for soft-tissue sarcoma are misguided and are in need of time- and risk-adapted methods.

News

A recent study compared the safety and efficacy of multiple chemotherapy agents in treating advanced liposarcoma.

Read More

By Marilynn Larkin

NEW YORK (Reuters Health) – While the overall risk of secondary cancers after Kaposi sarcoma (KS) has declined in people with HIV/AIDS, clinicians should be aware that certain cancers are becoming increasingly common in the highly active antiretroviral therapy (HAART) era compared with the pre-HAART era, researchers say.

Read More

Researchers compared a combination regimen with the current standard of care for first-line treatment of advanced soft-tissue sarcoma.

Read More

By Will Boggs MD

NEW YORK (Reuters Health) - Differences in the immunologic profiles of soft tissue sarcoma subtypes could have implications for treatment with immune checkpoint inhibitors, researchers report.

Read More

Quiz

In the highly active antiretroviral therapy era, which secondary malignancy to Kaposi sarcoma has emerged as a new risk for patients?

-----

A. Chronic myeloid leukemia

B. Chronic lymphocytic leukemia

C. Acute lymphocytic leukemia

D. Diffuse large B-cell lymphoma

-----

Read More

According to a recent study published in The LANCET Oncology, which treatment option is considered and should remain the standard of care for soft-tissue sarcoma?

-----

A. Gemcitabine

B. Doxorubicin

C. Eribulin 

D. Gemcitabine plus doxorubicin 

-----

Read More

Research in Review

Results from a large clinical trial argue against the inclusion of ifosfamide and etoposide to postoperative chemotherapy in patients with poorly responding osteosarcoma due to increasing toxicity and no improvement in event-free survival.

Read More

Age may be a significant determinant of the effectiveness of radiotherapy in patients with soft-tissue sarcoma undergoing surgery, according to a recent study.

Read More

Subscribe to Sarcoma